In pulmonary fibrosis, in vitro experiments have demonstrated that treatment with an anti-interleukin-23-specific antibody attenuated airway inflammation and reduced fibrosis by blocking interleukin-17A and -22 release. The gene discussed is IL17A; the disease is pulmonary fibrosis.